Key result
CMV viremia in the first year after pediatric primary lung transplantation was associated with an increased risk of death or retransplantation between days 90 and 365 (RR 4.1; 95% CI 1.1-14.5).
Why the study?
Does CMV viremia increase the risk of bronchiolitis obliterans or death and retransplantation in pediatric lung-transplant recipients?
Population
194 pediatric primary lung-transplant recipients
Comparison
Cytomegalovirus (CMV) viremia vs No CMV viremia
Design
Cohort
Follow-up
1 year
Authors
Loading...
Supports CMV monitoring in pediatric lung recipients; hypothesis-generating for whether prevention alters death or retransplant risk.
Cohort (n=194)
Does CMV viremia increase the risk of bronchiolitis obliterans or death and retransplantation in pediatric lung-transplant recipients?
Relative Risk: 4.1 (95% CI 1.1–14.5)
CMV viremia in the first year after pediatric primary lung transplantation is associated with a significantly increased risk of death or retransplantation between 90 and 365 days posttransplant.
Danziger‐Isakov et al. (2003) conducted a cohort in pediatric primary lung-transplant recipients (n=194). CMV viremia vs. No CMV viremia was evaluated on retransplantation or death between days 90 and 365 (RR 4.1, 95% CI 1.1-14.5). CMV viremia in the first year after pediatric primary lung transplantation was associated with an increased risk of death or retransplantation between days 90 and 365 (RR 4.1; 95% CI 1.1-14.5).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: